Gerresheimer AG logo

Gerresheimer AG (GRRMF)

Market Closed
5 Dec, 20:00
OTC PINK OTC PINK
$
51. 41
0
0%
$
1.74B Market Cap
29.23 P/E Ratio
5% Div Yield
0 Volume
5.32 Eps
$ 51.41
Previous Close
Day Range
51.41 51.41
Year Range
46.7 91.72
Want to track GRRMF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Earnings results expected in 80 days

Summary

GRRMF closed Friday higher at $51.41, an increase of 0% from Thursday's close, completing a monthly increase of 0% or $0. Over the past 12 months, GRRMF stock lost -23.54%.
GRRMF pays dividends to its shareholders, with the most recent payment made on Jun 10, 2025. The next estimated payment will be in In 6 months on Jun 10, 2026 for a total of $1.2975.
The last earnings report, released on Oct 10, 2025, missed the consensus estimates by -1.26%. On average, the company has fell short of earnings expectations by -0.59%, based on the last three reports. The next scheduled earnings report is due on Feb 26, 2026.
The stock of the company had never split.
The company's stock is traded on 1 different exchanges and in various currencies, with the primary listing on OTC PINK (USD).

GRRMF Chart

Gerresheimer appoints Uwe Röhrhoff as new interim CEO

Gerresheimer appoints Uwe Röhrhoff as new interim CEO

Medical equipment maker Gerresheimer said on Tuesday it had appointed Uwe Röhrhoff as interim CEO, effective November 1, 2025. He succeeds Dietmar Siemssen, who will step down as CEO by mutual agreement with the company's supervisory board on October 31.

Reuters | 1 month ago
Gerresheimer finds 2024 revenue-recognition issues after external probe

Gerresheimer finds 2024 revenue-recognition issues after external probe

Medical equipment maker Gerresheimer said it has obtained the initial findings from an investigation by an external law firm into the recognition of revenue and profit from bill-and-hold agreements in the 2024 financial year.

Reuters | 1 month ago
Gerresheimer AG (GRRMY) Q3 2025 Earnings Call Transcript

Gerresheimer AG (GRRMY) Q3 2025 Earnings Call Transcript

Gerresheimer AG (OTCPK:GRRMY) Q3 2025 Earnings Call October 9, 2025 2:30 AM EDT Company Participants Guido Pickert - Head of Investor Relations Dietmar Siemssen - CEO, Chairman of the Management Board and CEO of Plastics, Devices & Advanced Technologies Division Wolf Lehmann - CFO & Member of the Management Board Conference Call Participants Edward Hall - Stifel, Nicolaus & Company, Incorporated, Research Division Olivier Calvet - UBS Investment Bank, Research Division David Adlington - JPMorgan Chase & Co, Research Division Anna Snopkowski - KeyBanc Capital Markets Inc., Research Division Presentation Guido Pickert Head of Investor Relations Good morning, everyone, and welcome to our presentation of our preliminary Q3 2025 results. With us today are our CEO, Dietmar Siemssen; and our new CFO, Wolf Lehmann, who will lead you through our Q3 development and the financials.

Seekingalpha | 1 month ago

Gerresheimer AG (GRRMF) FAQ

What is the stock price today?

The current price is $51.41.

On which exchange is it traded?

Gerresheimer AG is listed on OTC PINK.

What is its stock symbol?

The ticker symbol is GRRMF.

Does it pay dividends? What is the current yield?

Yes, It pays dividends and the current yield is 5%.

What is its market cap?

As of today, the market cap is 1.74B.

What is the earnings per share?

The EPS is 1.15.

When is the next earnings date?

The next earnings report will release on Feb 26, 2026.

Has Gerresheimer AG ever had a stock split?

No, there has never been a stock split.

Gerresheimer AG Profile

Electronic Equipment, Instruments & Components Industry
Information Technology Sector
Mr. Dietmar Siemssen CEO
OTC PINK Exchange
DE000A0LD6E6 ISIN
DE Country
13,632 Employees
9 Jun 2025 Last Dividend
- Last Split
- IPO Date

Overview

Gerresheimer AG is an established leader in the production and distribution of specialized packaging solutions and drug delivery systems for the pharmaceutical, biotechnology, medical technology, diagnostics, cosmetics, glass containers, and food and beverage industries. With a rich history dating back to 1864, the company has grown to serve clients globally, with its headquarters situated in Düsseldorf, Germany. It operates through three main divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies, demonstrating a broad and innovative product portfolio designed to meet the complex needs of its clients in Germany and across the world.

Products and Services

  • Prefillable Syringes & Packaging Solutions: Gerresheimer AG offers a wide range of prefillable syringes, alongside plastic and glass packaging solutions such as vials, glass cartridges, and ampoules. These crucial components are designed for the safe and effective delivery of medications.
  • Bottles & Containers: The company produces both glass and plastic bottles and containers for various applications, along with specialized products like capsules, closures, applicators, and accessories to suit the diverse needs of the industries it serves.
  • Drug Delivery Programs: Gerresheimer offers comprehensive services in the development, industrialization, and contract manufacturing of drug delivery programs. Supported by project and quality management services, these solutions cater to inhalers, injection/autoinjectors, pen injectors, and infusion systems, emphasizing the significance of reliable drug delivery mechanisms.
  • Diagnostic & Medical Devices: The company manufactures diagnostic and medical devices, including point-of-care tests and laboratory disposables. It also offers chemical and technical bottles, diagnostic polymer vials, dropper bottles, PET bottles, and a variety of medical products such as lancing devices and infusion sets.
  • Cosmetic Packaging Solutions: Gerresheimer extends its expertise to the cosmetics industry by providing attractive and functional packaging solutions, including molded glass flacons and jars, tubular glass ampoules, droppers, samplers, vials, and a range of plastic packaging products.
  • Pharmaceutical, Laboratory, & Regulatory Affairs Services: The company is not only a manufacturer but also a service provider, offering a spectrum of pharmaceutical, laboratory, and regulatory affairs services to ensure compliance and facilitate the successful launch of products in various markets.

Contact Information

Address: Klaus-Bungert-Strasse 4
Phone: 49 211 61 81 00